PRNewsWire
16 Sept 2026, 12:45 UTC · 4d ago
Verdict
Headline takes no side. We score CODX +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Co-Diagnostics and ReadyGo announced a collaboration to evaluate using GoCollect sample-preparation with the Co-Dx PCR platform for blood-based molecular testing, starting with Ebola.
Newannounced today, Sep 16, 2026
More positive than 76% of claims this week
The collaboration aims to establish if blood is a compatible sample type for the Co-Dx PCR platform, a compatibility that has not yet been established.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
So whatBecause feasibility is still 'underway,' any negative result in the coming months would cap the platform's growth to swab-only markets.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company is collaborating to expand its PCR platform into blood-based testing, potentially opening new markets for HIV and hepatitis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
−17.0%
Price is moving against the score
$0.9457 vs $1.14 close before publication (Sep 15) · not market-adjusted
CODX chart →
